Rutgers Cancer Institute of New Jersey

Rutgers, The State University of New Jersey

New Brunswick, NJ

Sorting 5 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Not yet accepting

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
  • Has results

Accepting patients

LINKER-MM4

Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2

Accepting patients

LINKER-MM1

First in Human (FIH) Study of Linvoseltamab (REGN5458) in Patients With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2
  • Has results

Accepting patients

Cord Blood Units for Neutrophil Recovery

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
  • Cord Blood
  • Observational Trial